Polomar Health Q2 Revenue Jumps to $1.5M, Turns Profitable, But Going Concern and Material Weaknesses Persist
PMHS has more than doubled off its 52-week low of $0.065.
Summary
Polomar Health Services reported a dramatic revenue increase and a quarterly profit, but the company still faces substantial doubt about its ability to continue as a going concern and has material weaknesses in internal controls.
Key Events · Earnings and Guidance · PMHS
-
Revenue Surges to $1.5M
Q2 2026 revenue was $1,528,705, up from $5,470 in Q2 2025. Six-month revenue reached $2,534,224, driven by prescription fulfillment for a single customer.
-
Company Turns Profitable
Net income was $200,358 for Q2 2026 and $174,981 for the first half, compared to losses of $605,563 and $1,062,418 in the prior-year periods.
-
Going Concern Warning Repeats
Management states substantial doubt exists about the company's ability to continue as a going concern, citing an accumulated deficit of $13,526,169 and dependence on raising capital.
-
Material Weaknesses in Controls
The company disclosed material weaknesses in internal control over financial reporting, including inadequate segregation of duties and insufficient accounting expertise.
Analysis · PMHS · Life Sciences
Polomar Health Services reported Q2 2026 revenue of $1.53 million, up from just $5,470 a year earlier, and swung to a net profit of $200,358. The company's pharmacy business is scaling rapidly, but the filing also repeats a going concern warning and discloses material weaknesses in financial controls. The company remains highly dependent on a single customer and faces a $20 million lawsuit from a former partner.
At the time of this filing, PMHS was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.07 to $960,000.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.